AWP Settlements Unlikely To Resolve Pricing Issue, State Fraud Chief Says
Executive Summary
Federal health care fraud prosecutions will not be sufficient to resolve the issues surrounding AWP price reporting, National Association of State Medicaid Fraud Control Units President Christopher Abruzzo told the 340B Coalition annual conference in Washington, D.C. July 16
You may also be interested in...
Medicare AWP Reform Would Cause Oncologists To Drop Patients, ASCO Says
One in five oncologists will drop their Medicare patients if the AWP reform provisions of the House or Senate Medicare bills are enacted, the American Society of Clinical Oncology says
Medicare Rx Conference Could Last Into Fall; AWP One Sticking Point
The House/Senate Medicare negotiations could last well into the fall, a staffer to Senate Majority Leader Bill Frist (R-Tenn.) predicted July 1
Bayer Drug Prices To Be Monitored By HHS Under Medicaid Fraud Settlement
Bayer will provide states and the federal government with the average selling prices of its drugs to help them set reasonable reimbursement rates under a tentative settlement agreement with the Justice Department.